SecBot SecBot

BIXT drug pipeline

BIOXYTRAN, INC · 1 rated drug
$0.0230
+4.5% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseNot applicable (dietary supplement, not a drug)
Time to marketAlready in production and available as a dietary supplement in the U.S. Commercial launch in the UAE and Gulf Cooperation Council markets is pending local product registration, with timing uncertain.

A-SUQAR partially hydrolyzed guar gum (PHGG) formulation Updated Nov 7

What to watch

Watch for news on UAE product registration and initial commercial launch by Khoury Medical, which would be the first real revenue test for A-SUQAR. Also monitor Bioxytran's financing activities and the ProLectin-M registrational trial (planned 408-patient study), as the company's going-concern status makes its ability to fund operations the dominant risk.

Bull case
  • A-SUQAR received a government-issued Free Sale Certificate on November 4, 2026, legalized for use in the UAE, opening a path to a region where roughly 7.5 million adults have diabetes (UAE, Saudi Arabia, Kuwait).
  • A commercial distribution agreement with Khoury Medical LTD was signed in February 2026, providing a route-to-market without heavy upfront capital spending by Bioxytran.
  • The product is already in production and can generate early revenue for a company that reported only $177,795 in trailing twelve-month revenue as of June 2026.
Bear case
  • A-SUQAR is a dietary supplement, not an FDA-approved drug. The FDA does not evaluate or approve supplement structure/function claims before marketing, so there is no regulatory barrier protecting the product from competitors.
  • Bioxytran is a pre-revenue clinical-stage biotech with an auditor going-concern warning (Fruci & Associates II, PLLC, April 2026 10-K) and negative working capital, raising questions about its ability to fund commercialization.
  • The stock trades at $0.023 on the OTCQB with minimal volume (20,000 shares on Nov 5), no tracked institutional holders, and no analyst coverage, indicating very limited investor interest.